184 related articles for article (PubMed ID: 23371258)
1. [Tailored management of chronic myeloid leukemia].
Hochhaus A; La Rosée P
Internist (Berl); 2013 Feb; 54(2):155-6, 158-60, 162-3. PubMed ID: 23371258
[TBL] [Abstract][Full Text] [Related]
2. Molecular basis for therapeutic decisions in chronic myeloid leukemia patients after allogeneic bone marrow transplantation.
Román J; Alvarez MA; Torres A
Haematologica; 2000 Oct; 85(10):1072-82. PubMed ID: 11025600
[TBL] [Abstract][Full Text] [Related]
3. [Chronic lymphocytic leukemia. Treatment and genetic risk profile].
Stilgenbauer S; Hallek M
Internist (Berl); 2013 Feb; 54(2):164, 166-70. PubMed ID: 23371259
[TBL] [Abstract][Full Text] [Related]
4. Molecular analysis of lineage-specific chimerism and minimal residual disease by RT-PCR of p210(BCR-ABL) and p190(BCR-ABL) after allogeneic bone marrow transplantation for chronic myeloid leukemia: increasing mixed myeloid chimerism and p190(BCR-ABL) detection precede cytogenetic relapse.
Serrano J; Roman J; Sanchez J; Jimenez A; Castillejo JA; Herrera C; Gonzalez MG; Reina L; Rodriguez MC; Alvarez MA; Maldonado J; Torres A
Blood; 2000 Apr; 95(8):2659-65. PubMed ID: 10753848
[TBL] [Abstract][Full Text] [Related]
5. Measuring minimal residual disease in chronic myeloid leukemia: fluorescence in situ hybridization and polymerase chain reaction.
Hughes TP; Branford S
Clin Lymphoma Myeloma; 2009; 9 Suppl 3():S266-71. PubMed ID: 19778851
[TBL] [Abstract][Full Text] [Related]
6. Chronic myeloid leukemia: standard treatment options.
Frame D
Am J Health Syst Pharm; 2006 Dec; 63(23 Suppl 8):S10-4; quiz S21-2. PubMed ID: 17106015
[TBL] [Abstract][Full Text] [Related]
7. Diagnosing and managing advanced chronic myeloid leukemia.
Deininger MW
Am Soc Clin Oncol Educ Book; 2015; ():e381-8. PubMed ID: 25993200
[TBL] [Abstract][Full Text] [Related]
8. [Acute myeloid leukemia. Genetic diagnostics and molecular therapy].
Schlenk RF; Döhner K; Döhner H
Internist (Berl); 2013 Feb; 54(2):171-8. PubMed ID: 23358744
[TBL] [Abstract][Full Text] [Related]
9. Best Practices in Chronic Myeloid Leukemia Monitoring and Management.
Soverini S; De Benedittis C; Mancini M; Martinelli G
Oncologist; 2016 May; 21(5):626-33. PubMed ID: 27032870
[TBL] [Abstract][Full Text] [Related]
10. Molecular monitoring and mutations in chronic myeloid leukemia: how to get the most out of your tyrosine kinase inhibitor.
Baccarani M; Soverini S; De Benedittis C
Am Soc Clin Oncol Educ Book; 2014; ():167-75. PubMed ID: 24857074
[TBL] [Abstract][Full Text] [Related]
11. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts.
Sillaber C; Mayerhofer M; Agis H; Sagaster V; Mannhalter C; Sperr WR; Geissler K; Valent P
Wien Klin Wochenschr; 2003 Aug; 115(13-14):485-504. PubMed ID: 13677268
[TBL] [Abstract][Full Text] [Related]
12. Prediction of relapse by day 100 BCR-ABL quantification after allogeneic stem cell transplantation for chronic myeloid leukemia.
Asnafi V; Rubio MT; Delabesse E; Villar E; Davi F; Damaj G; Hirsch I; Dhédin N; Vernant JP; Varet B; Buzyn A; Macintyre E
Leukemia; 2006 May; 20(5):793-9. PubMed ID: 16541140
[TBL] [Abstract][Full Text] [Related]
13. Persistence of myeloid progenitor cells expressing BCR-ABL mRNA after allogeneic bone marrow transplantation for chronic myelogenous leukemia.
Pichert G; Alyea EP; Soiffer RJ; Roy DC; Ritz J
Blood; 1994 Oct; 84(7):2109-14. PubMed ID: 7919323
[TBL] [Abstract][Full Text] [Related]
14. Molecular analysis of transient cytogenetic relapse after allogeneic bone marrow transplantation for chronic myeloid leukaemia.
Lin F; Kirkland MA; van Rhee FV; Chase A; Coulthard S; Bungey J; Goldman JM; Cross NC
Bone Marrow Transplant; 1996 Dec; 18(6):1147-52. PubMed ID: 8971386
[TBL] [Abstract][Full Text] [Related]
15. Chronic myeloid leukemia in 2007.
Sessions J
Am J Health Syst Pharm; 2007 Dec; 64(24 Suppl 15):S4-9. PubMed ID: 18056931
[TBL] [Abstract][Full Text] [Related]
16. The risk of residual molecular and cytogenetic disease in patients with Philadelphia-chromosome positive first chronic phase chronic myelogenous leukemia is reduced after transplantation of allogeneic peripheral blood stem cells compared with bone marrow.
Elmaagacli AH; Beelen DW; Opalka B; Seeber S; Schaefer UW
Blood; 1999 Jul; 94(2):384-9. PubMed ID: 10397704
[TBL] [Abstract][Full Text] [Related]
17. Comparison of genomic DNA and cDNA for detection of residual disease after treatment of chronic myeloid leukemia with allogeneic bone marrow transplantation.
Zhang JG; Lin F; Chase A; Goldman JM; Cross NC
Blood; 1996 Mar; 87(6):2588-93. PubMed ID: 8630427
[TBL] [Abstract][Full Text] [Related]
18. Allogeneic stem cell transplantation for patients with chronic myeloid leukemia and acute lymphocytic leukemia after Bcr-Abl kinase mutation-related imatinib failure.
Jabbour E; Cortes J; Kantarjian HM; Giralt S; Jones D; Jones R; Giles F; Andersson BS; Champlin R; de Lima M
Blood; 2006 Aug; 108(4):1421-3. PubMed ID: 16601247
[TBL] [Abstract][Full Text] [Related]
19. Predicting relapse of chronic myelogenous leukemia after allogeneic bone marrow transplantation by bcr-abl mRNA and DNA fingerprinting.
Okamoto R; Harano H; Matsuzaki M; Motomura S; Maruta A; Kodama F; Mohri H; Okubo T
Am J Clin Pathol; 1995 Nov; 104(5):510-6. PubMed ID: 7572810
[TBL] [Abstract][Full Text] [Related]
20. Chronic myeloid leukemia: 2020 update on diagnosis, therapy and monitoring.
Jabbour E; Kantarjian H
Am J Hematol; 2020 Jun; 95(6):691-709. PubMed ID: 32239758
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]